Cantor analyst Mara Goldstein reiterated a Buy rating on NewLink Genetics Corp (NASDAQ:NLNK) with a price target of $48, following the company’s fourth quarter results, posting EPS of $4.05 per share, which included licensing and other revenues from partnerships, most notably a deal with Roche for development rights to NLG919 and the IDO/TDO platform overall.
Goldstein noted, “NewLink is working in the rapidly developing field of cancer immunotherapy and has a novel approach based on a solid scientific foundation, two platforms (therapeutic vaccine and small molecule), and a clinical program with depth. In the past two months, NewLink has added a major collaboration with Roche for the IDO/TDO program (small molecule) and a partnership for commercialization of the Ebola program with Merck, a major player in the vaccine market.”
Furthermore, “The company is also approaching a second interim analysis for the HyperAcute Pancreas Phase III trial (at 50% of events, or 333 deaths). With the possibility of early stopping of this trial at interim, news from the Ebola efficacy program, incremental indoximod data and news from the Roche partnership for NLG919, we think the shares can support a valuation of $48.”
According to TipRanks.com, which measures analysts’ and bloggers’ success rate based on how their calls perform, analyst Mara Goldstein has a total average return of 24.0% and a 78.6% success rate. Goldstein has a 32.6% average return when recommending NLNK, and is ranked #191 out of 3483 analysts.